Matthew Voss, MD
Interventional Cardiology · Baltimore, MDNPI 1104830579
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 86.0% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $26,995, more than ten times the $1,097 reported in 2019.
Across 131 payments — averaging $253.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$29K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Chiesi USA, Inc.$266
- Abiomed$253
- Novartis$240
- plus $672 from 15 others
Across 272 payments — averaging $9426.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.4M
- Janssen Research & Development, LLC$777K
- Boehringer Ingelheim$339K
- Boehringer Ingelheim International GmbH$16K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
What the payments were for
- Consulting fees$4,74414%
- Speaking & faculty fees$18,83157%
- Travel & lodging$4,24913%
- Food & beverage$5,34816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 51 | $28,537 |
| Edwards Lifesciences | 16 | $2,163 |
| Boston Scientific | 15 | $1,041 |
| Chiesi USA, Inc. | 4 | $266 |
| Abiomed | 3 | $253 |
| Novartis | 12 | $240 |
| Johnson & Johnson | 13 | $127 |
| Shockwave Medical, Inc | 1 | $124 |
| Amgen | 2 | $106 |
| AstraZeneca | 1 | $62 |
| Novo Nordisk | 2 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| Cardiva Medical, Inc. | 1 | $27 |
| Teleflex LLC | 1 | $27 |
| Terumo Medical Corporation | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $19 |
| Biotronik Inc. | 1 | $18 |
| Atricure, Inc. | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,172 in reported general payments places this provider in the 80th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $246,587 |
| XareltoRivaroxaban | 40 | $57,846 |
| EntrestoSacubitril/Valsartan | 24 | $46,718 |
| Repatha SureclickEvolocumab | 53 | $41,396 |
| Metoprolol Succinate | 289 | $5,845 |
| Rosuvastatin Calcium | 139 | $4,935 |
| Ezetimibe | 84 | $4,602 |
| Atorvastatin Calcium | 228 | $3,319 |
| Pravastatin Sodium | 38 | $1,347 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $1,243 |
| Chlorthalidone | 35 | $1,007 |
| Valsartan | 25 | $994 |
| Labetalol Hcl | 24 | $964 |
| ClopidogrelClopidogrel Bisulfate | 64 | $816 |
| Carvedilol | 63 | $793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $127 | $57,84640 claims |
| NovartisEntresto | $240 | $46,71824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Jon ResarBaltimore$40K
- Faisal RahmanBaltimore$36K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
- Hani AlkhatibBaltimore$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.